Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
26 oct. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
10 oct. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
06 oct. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
26 sept. 2023 07h30 HE
|
Inozyme Pharma Inc.
- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the...
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
20 sept. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 sept. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
08 août 2023 08h30 HE
|
Inozyme Pharma Inc.
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate (PPi) to...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 août 2023 16h01 HE
|
Inozyme Pharma Inc.
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
01 août 2023 16h01 HE
|
Inozyme Pharma Inc.
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...